Search
Search results
-
Case for Mutual Recognition of Drug Approvals
This study aims to measure the difference in access to new medicines that results from duplication of effort in Canada. By compiling a list of new drugs approved in Canada between 2005-2011/12 (Health Canada moved from calendar-year to fiscal-year ...
-
Stronger intellectual property for pharmaceuticals would benefit Canadians
Appeared in the Globe and Mail Economy Lab Canada's lagging intellectual property (IP) protections for pharmaceutical innovators are a key issue to be settled in the Comprehensive Economic and Trade Agreement (CETA) negotiations with the European ...
-
Cutting Canada's Drug Lag while Improving Safety
Appeared in the Guelph Mercury New medicines are a central component of modern medical care, treating illness effectively, providing more comfortable treatment regimes, extending life and reducing disability, and sometimes offering new treatment options ...
-
Federal Delays in Approving New Medicines 2013
This study measures delays in the approval of new medicines by Health Canada and provides patients with the information they need in order to determine whether the time they wait for access to new medicines in Canada is unnecessarily long. Our findings ...